<DOC>
	<DOCNO>NCT00352118</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , cisplatin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together radiation therapy work treat patient locally advanced head neck cancer . The doctor also want find patient receive treatment need feed tube 1 year start treatment .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feed tube dependency 12 month patient locally advanced head neck cancer treat induction chemotherapy comprise docetaxel , cisplatin , fluorouracil follow cisplatin reduced-dose radiotherapy . Secondary - Determine progression-free , disease-free , overall survival patient treat regimen . - Determine pattern failure patient treat regimen . - Evaluate quality life patient treat regimen . - Assess pre- post-treatment swallowing ability patient impact quality life . Tertiary - Quantify salivary flow rate patient receive chemotherapy radiotherapy head neck malignancy . - Evaluate quality saliva examine total protein concentration . - Quantify proangiogenic cytokine ( interleukin [ IL ] -1 , IL-6 , IL-8 , vascular endothelial growth factor ) saliva patient . - Determine degree mucositis xerostomia patient receive chemotherapy radiotherapy head neck malignancy . - Compare salivary flow rate grade mucositis xerostomia patient receive chemotherapy radiotherapy head neck malignancy . OUTLINE : This pilot study . - Induction therapy : Patients receive docetaxel IV 1 hour cisplatin IV 1 hour day 1 follow fluorouracil IV continuously day 1- 4 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) day 5-14 pegfilgrastim SC day 5 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Patients achieve partial clinical complete response proceed chemoradiotherapy 3 week later . - Chemoradiotherapy : Patients receive cisplatin IV 1 hour day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients also undergo concurrent reduced-dose radiotherapy 5 day week 6 week . - Surgery : Approximately 6 8 week complete chemoradiotherapy , patient residual neck disease disease initially stag N2 great undergo neck dissection . Saliva collect periodically measure flow rate quality ; quantify proangiogenic cytokine ( interleukin [ IL ] -1 , IL-6 , IL-8 vascular endothelial growth factor ) ; examine grade mucositis xerostomia . Quality life assess baseline , chemoradiotherapy , 1 month last radiation treatment , every 3 month 1 year , every 6 month 1 year . After completion study treatment , patient follow periodically 5 year annually thereafter . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm squamous cell carcinoma head neck Stage IVA IVB disease Stage III disease allow provided patient may benefit organ preservation patient refuse surgery Measurable evaluable disease ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL OR glomerular filtration rate ≥ 60 mL/min Bilirubin normal Alkaline phosphatase ( AP ) AST ALT must within follow range : AP normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Salivary gland , sinus , nasopharyngeal primary disease Evidence distant metastatic disease Pregnant nursing Positive pregnancy test ( Fertile patient must use effective contraception study treatment 3 month completion study treatment ) Other malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , malignancy stage nature disease unlikely affect survival next 3 year Peripheral neuropathy ≥ grade 2 Hearing loss ≥ grade 2 Severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 and/or cisplatin platinum analog Poor nutritional status , opinion investigator Active infection Active ischemic heart disease Myocardial infarction within past 6 month Prior radiotherapy clavicle Prior chemotherapy Prior surgery primary tumor except biopsy Concurrent amifostine investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>oral complication radiation therapy</keyword>
	<keyword>oral complication chemotherapy</keyword>
	<keyword>mucositis</keyword>
	<keyword>xerostomia</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>